The AMR Narrative

Carbapenem-resistant Pseudomonas aeruginosa (CRPA)

Although great care has been taken in the compilation and preparation of all directory entries to ensure accuracy, we cannot accept responsibility for any errors or omissions. Any medical information is provided for education/information purposes only and is not designed to replace medical advice by a qualified medical professional. Please see our disclaimer at the bottom of this entry.


What is Carbapenem-resistant Pseudomonas aeruginosa (CRPA)?

Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a type of Pseudomonas aeruginosa bacteria resistant to carbapenems, a type of last-line antibiotics used to treat serious multidrug-resistant bacterial infections.

Unfortunately, CRPA bacteria can produce substances (called carbapenemases) that break down carbapenems and other so-called beta-lactams antibiotics (such as penicillin), making these medications ineffective. Some CRPA bacteria are even resistant to all available antibiotics, causing infections very difficult to treat.

Moreover, CRPA can share the genetic code with other bacteria, rapidly spreading resistance. That is why CRPA is considered a serious public health threat, and has been listed among the top priority bacterial pathogens to guide discovery, research and development of new antibiotics by the World Health Organization (WHO).

What is Pseudomonas aeruginosa?

To understand CRPA, it is important to know what Pseudomonas aeruginosa is.

Pseudomonas aeruginosa is a bacterium (bacteria), gram-negative, and rod-shaped.

It can cause various types of infections ranging from mild to serious ones. Life-threatening conditions primarily occur in healthcare settings, such as hospitals and nursing homes, and affect people at high risk, such as those ones with a weakened immune system.

Where can Pseudomonas aeruginosa be found?

Pseudomonas aeruginosa is commonly found in the environment, in soil and especially in water.

Taps, sinks, toilets, drains, plumbing parts, hot tubs, and inadequately chlorinated swimming pools are common reservoirs. In hospital settings these bacteria can be found also in soap bars, sanitizers, disinfecting solutions, respiratory therapy equipment, endoscopes, and endoscope washers.

Occasionally, Pseudomonas aeruginosa can be present in moist parts of the body, like armpits or genital area.

How can Pseudomonas aeruginosa spread?

Since Pseudomonas aeruginosa lives in the environment, can be spread to people when they are exposed to water or soil contaminated with these microorganisms.

In healthcare settings bacteria can spread from person to person by skin contact (through healthcare workers’ contaminated hands), or contaminated equipment or surfaces.

Pseudomonas aeruginosa infections are commonly acquired in hospitals or nursing homes.


Which infections can Pseudomonas aeruginosa cause?

Pseudomonas aeruginosa can cause mild infections in healthy people, but also life-threatening infections in people considered at risk (see Who is at risk of a Pseudomonas aeruginosa infection).

These infections may include:

• Skin and soft tissue infections. Bacteria can infect skin (for example, hot-tub folliculitis, a mild infection of hair roots), and even cause serious deep infections of muscles, tendons, ligaments, and fat. These conditions are more common in people with pressure sores, burns, and wounds due to injuries or surgery.
• Keratitis. It occurs when Pseudomonas aeruginosa bacteria infect and damage the cornea (the transparent and external part of the eye), often permanently. It may result from injuries, or from contamination of contact lenses or contact lens solution.
• External otitis. Water containing the bacteria can enter the ear during swimming, causing an infection of the ear canal skin. It can turn into a severe infection, especially in patients with diabetes.
• Bacteremia. When bacteria overcome the defence line of the skin, it can travel inside the bloodstream, and infect almost any site in the body.
• Pneumonia. The infection of the lung is more common in patients hospitalized with tracheal intubation and mechanical ventilation, or with chronic lung diseases (such as cystic fibrosis).
• Endocarditis. In this serious and potentially deadly condition, bacteria stick to one of the valves inside the heart after spreading into the bloodstream.
• Urinary tract infections. These types of infections are more likely in people with urinary catheters.
• Osteomyelitis. It occurs when Pseudomonas aeruginosa bacteria target a bone through the bloodstream.
• Meningitis. In this condition, bacteria can infect the meninges (the membranes covering the brain and spinal cord).
• Sepsis. It is the extreme and overactive response of the body to an infection. Sepsis is a life-threatening emergency, and requires immediate treatment.


Who is at risk of a Pseudomonas aeruginosa infection?

Anyone can develop a Pseudomonas aeruginosa infection, but certain groups of people are at greater risk than others, including people:

• with chronic illnesses, such as cancer, diabetes, cystic fibrosis, kidney or liver diseases, rheumatoid arthritis;
• with a weakened immune system, such as from HIV, immunosuppressants (medications which slow or stop the response of the immune system), or cancer chemotherapy;
• with urinary or intravenous catheters;
• with breathing tubes;
• with severe burns;
• with wounds due to surgical interventions;
• who are in healthcare facilities, such as hospitals.

How are Pseudomonas aeruginosa infections diagnosed?

To correctly diagnose an infection caused by Pseudomonas aeruginosa, first of all your physician will perform a physical examination and ask you about symptoms and risk factors. Guided by these elements, your doctor will be able to choose the most appropriate diagnostic tests.

Laboratory tests can identify Pseudomonas aeruginosa using a sample taken from an area of the patient’s body likely to contain the microbe (for example, blood or other tissue or fluid). These samples are sent to a laboratory to grow the microorganism over time using a media on a petri dish (culture) and identify it. Then susceptibility tests can be carried out to determine which antibiotics are most effective against it, to start the most appropriate antibiotic therapy. Understanding which antibiotic will work best is especially key to carbapenem-resistant Pseudomonas aeruginosa (CRPA) as this type of resistant Pseudomonas aeruginosa bacteria may only respond to certain medicines.

Novel molecular DNA tests can not only rapidly detect the bacteria directly in a specimen but at same time provide antibiotic resistance results, making it much easier for the physician to choose appropriate antibiotics. In some cases, they may respond to none.

Finally, depending on the type of infection, your physician may recommend additional tests, such as imaging tests.


How are Pseudomonas aeruginosa infections treated?

As Pseudomonas aeruginosa is a bacterium, therapy is represented by antibiotics. The antibiotic may vary according to the type and severity of the infection, and the results of susceptibility tests. Indeed, some infections, such as those ones caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA), are resistant to several antibiotics.

Depending on the site and the severity of infection, the medication could be in the form of eye drops, ear drops, creams applied to the skin, or tablets to swallow. Severe infections may require intravenous antibiotics (the medication is given through a drip or a tube).

Mild infections can be easily treated with antibiotics at home. However, severe infections require to be treated in hospital, and need additional therapies.

Unfortunately, due to the increasing resistance to the available antibiotics, Pseudomonas aeruginosa infections are becoming more difficult to treat, and sometimes more than one antibiotic is needed.

How can Pseudomonas aeruginosa infections be prevented?

Following these precautions can lower your risk of getting a Pseudomonas aeruginosa infection. Moreover, they help to reduce your chances of spreading bacteria to others, as well.

• Wash your hands thoroughly and regularly with soap and running water. Then dry them with a clean towel, or a disposable paper towel. If you are not able to wash your hands, you can use an alcohol-based hand sanitizer. Remember: hand hygiene is your best protection against infections.
• Clean surfaces. Use disinfecting products to clean especially high-touch surfaces, such as your cell phone, doorknobs, and light switches.
• Avoid unclean swimming pools and hot tubs. Make sure they are properly maintained and chlorinated.
• Drink clean water. If you do not have clean water available, drink bottled, canned, or boiled water.
• Wash fruits and vegetables before eating.
• Keep wounds clean and covered with dry and sterile bandages until they heal, to prevent the bacteria from spreading.



Disclaimer: The information provided on this website is intended for educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Reliance on any information provided on this website is solely at your own risk. The website owners and authors are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. It is recommended that you consult a qualified healthcare professional for individualised medical and health-related guidance.

Dr Marie-Anne Bouldouyre

Dr Marie-Anne Bouldouyre is an infectious diseases physician and hospital practitioner in Paris. Twelve years of clinical work in a suburban hospital shaped her understanding of access to care, patient relationships, and the daily reality of antimicrobial resistance.

Since 2022, she has led the Regional Antibiotic Stewardship Centre in Île-de-France and coordinates the national network, working with a multidisciplinary team to promote responsible antibiotic use and strengthen collaboration among healthcare professionals. She also continues to manage complex infections at Saint-Louis Hospital.

Convinced that antimicrobial resistance cannot be tackled by healthcare workers alone, she advocates for the active involvement of patients : understanding, questioning, and taking part in decisions about antibiotics. Their stories are essential to making this issue visible and concrete.

She is proud to collaborate with initiatives such as The AMR Narrative and hopes to foster similar projects in France to give patients a voice in this shared fight.

Dr Erva Cinar

Dr Erva Cinar is a London based paediatric resident doctor and clinical researcher with interest in infectious diseases.

She is currently completing a Master’s in Public Health at the London School of Hygiene & Tropical Medicine. Through the World Medical Association’s Junior Doctor’s Network (WMA-JDN) AMR Working Group, she engages in policy and advocacy on antimicrobial resistance and stewardship at global level.

Alongside her clinical and academic roles, she works with the Royal College of Paediatrics and Child Health (RCPCH) and the International Child Health Group (ICHG); leads on organising teaching resources and educational events to improve research skills for UK paediatric trainees and for global child health professionals.

Hamu Madzedze

Hamu Madzedze is a seasoned Zimbabwean journalist with over 15 years’ experience.

She previously worked for the Zimbabwe Broadcasting Corporation as a reporter and sub-editor, before establishing an independent website, 365HealthDiaries, which focuses on health and gender issues.

She holds a BA in Media Studies and a BA (Special Honours) in Communication and Media from the Zimbabwe Open University, as well as a diploma from the Christian College of Southern Africa.

Her work has been recognised with several awards, including the Global AMR Special Mention Award (2024), the Sexual Health Rights and Equity Fellowship Special Mention Award (2025), and the Merck Foundation Award (2024) for outstanding coverage of health issues, gender, infertility, and genital mutilation, where she achieved third position in the Online Category.

Hamu is passionate about addressing AMR through the media.

Jomana F. Musmar

Dr. Jomana Musmar is a distinguished global policy expert and proactive leader with over fifteen years of government experience in strategic planning, operational design, and policy execution. Renowned for simplifying complex topics with expertise and diplomacy, she has spearheaded innovative solutions to global health challenges, shaped impactful policies, and advanced national and international missions.

As the Executive Director of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, she established and led the council’s operations, liaising with over 600 experts, worldwide, across government, industry, and academia. Her efforts culminated in the development of critical recommendations addressing antimicrobial resistance and interrelated One Health issues, influencing both domestic and global health strategies.

In her tenure as Deputy Director of Strategic Initiatives for the Office of Infectious Diseases and HIV/AIDS Policy, at the US Department of Health and Human Services, Dr. Musmar oversaw the formulation and implementation of national health strategies for vaccines and a range of infectious diseases including HIV/AIDS and viral hepatitis. Her leadership and technical expertise facilitated groundbreaking policies during national emergencies, including responses to the COVID-19 pandemic, and initiatives to combat congenital syphilis and childhood vaccination disruptions. Dr. Musmar holds a Ph.D. in Biodefense from George Mason University, a Master’s degree in Biomedical Science policy and Advocacy from Georgetown University, and is a Lean Six Sigma Black Belt. Fluent in English and Arabic, she is a sought-after speaker and advisor, having represented the United States at premier global health conferences.

Her published works on antimicrobial resistance, pandemic preparedness, and national health security underscore her reputation as a thought leader and innovator in public health and biodefense.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.